Status:

UNKNOWN

Effect of Thrombin-containing Collagen-based Hemostatic Matrix

Lead Sponsor:

Asan Medical Center

Conditions:

Pancreatic Tumor

Eligibility:

All Genders

20-80 years

Phase:

PHASE4

Brief Summary

Under the hypothesis that collagen-based hemostatic agents improve the suppression of leakage of hemostatic pancreatic fluid at the surgical site during surgery, thrombin-containing collagen-based hem...

Detailed Description

1. Synopsis * Title: Randomized controlled Study to evaluate the Effect of Thrombin-containing Collagen-based Hemostatic Matrix on Prevention of Pancreatic fistula after Pancreatectomy * Study ...

Eligibility Criteria

Inclusion

  • Age: 20-80 years at the day of enrollment
  • Performance: ECOG 0-2
  • Patients who was scheduled for pancreatectomy due to benign or malignant tumor
  • No distant metastasis
  • Bone marrow function: WBC at least 3,000 / mm3, Platelet count at least 100,000 / mm3
  • Liver function: AST / ALT less than 3 times upper limit of normal
  • Kidney function: Creatinine no greater than 1.5 times upper limit of normal.
  • Patients who consented to and signed the consent

Exclusion

  • Those with active or uncontrolled infections
  • Those with severe psychiatric / neurological disorders
  • Alcohol or other drug addicts
  • Patients included in other clinical studies that may affect this study
  • Patients who cannot follow the directions of the researcher
  • Those with uncontrolled heart disease
  • Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (cirrhosis, chronic kidney failure, heart failure, etc.)
  • Pelvic tumor, benign tumor, malignant tumor in other organs
  • pregnant or planning on becoming pregnant during the follow-up period
  • undergoing lymphatic or coagulation disease
  • known sensitivity or allergy to bovine and/or porcine substance(s)

Key Trial Info

Start Date :

February 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2020

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04357483

Start Date

February 1 2018

End Date

September 30 2020

Last Update

April 28 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asan medical center

Seoul, South Korea, 05505